$1,460,000 of BIOGEN lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill. Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income. Trade-related public policy around tariffs and intellectual property, no related bills"
You can find more data on corporate lobbying on Quiver Quantitative.
BIIB Congressional Stock Trading
Members of Congress have traded $BIIB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 01/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BIIB Insider Trading Activity
BIIB insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 3,408 shares for an estimated $665,664.
- NICOLE MURPHY (Head of Pharm Ops and Tech) purchased 3 shares for an estimated $585
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIIB Hedge Fund Activity
We have seen 459 institutional investors add shares of BIIB stock to their portfolio, and 380 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 8,138,103 shares (+632.0%) to their portfolio in Q4 2025, for an estimated $1,432,224,746
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,365,462 shares (-75.8%) from their portfolio in Q4 2025, for an estimated $768,277,657
- BOSTON PARTNERS added 1,720,595 shares (+inf%) to their portfolio in Q4 2025, for an estimated $302,807,514
- PACER ADVISORS, INC. removed 1,451,249 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $255,405,311
- POINT72 ASSET MANAGEMENT, L.P. removed 1,059,709 shares (-27.4%) from their portfolio in Q4 2025, for an estimated $186,498,186
- FRED ALGER MANAGEMENT, LLC added 796,735 shares (+39074.8%) to their portfolio in Q4 2025, for an estimated $140,217,392
- INVESCO LTD. removed 762,686 shares (-31.5%) from their portfolio in Q4 2025, for an estimated $134,225,109
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIIB Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 01/30/2026
- HSBC issued a "Reduce" rating on 12/10/2025
- Stifel issued a "Buy" rating on 11/06/2025
- RBC Capital issued a "Outperform" rating on 10/31/2025
To track analyst ratings and price targets for BIIB, check out Quiver Quantitative's $BIIB forecast page.
BIIB Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 19 analysts offer price targets for $BIIB in the last 6 months, with a median target of $202.0.
Here are some recent targets:
- Mohit Bansal from Wells Fargo set a target price of $250.0 on 04/20/2026
- David Amsellem from Piper Sandler set a target price of $214.0 on 04/14/2026
- Srikripa Devarakonda from Truist Securities set a target price of $189.0 on 04/13/2026
- Geoff Meacham from Citigroup set a target price of $190.0 on 04/13/2026
- Matthew Harrison from Morgan Stanley set a target price of $200.0 on 04/10/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $237.0 on 04/02/2026
- Sumant Kulkarni from Canaccord Genuity set a target price of $245.0 on 04/01/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
